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Abstract
Women with polycystic ovary syndrome (PCOS) have a considerable risk of metabolic dysfunction. This review aims to present contemporary
knowledge on obesity, insulin resistance and PCOS with emphasis on the diagnostic and methodological challenges encountered in research
and clinical practice. Variable diagnostic criteria for PCOS and associated phenotypes are frequently published. Targeted searches were
conducted to identify all available data concerning the association of obesity and insulin resistance with PCOS up to September 2016. Articles
were considered if they were peer reviewed, in English and included women with PCOS. Obesity is more prevalent in women with PCOS, but
studies rarely reported accurate assessments of adiposity, nor split the study population by PCOS phenotypes. Many women with PCOS have
insulin resistance, though there is considerable variation reported in part due to not distinguishing subgroups known to have an impact on
insulin resistance as well as limited methodology to measure insulin resistance. Inflammatory markers are positively correlated with androgen
levels, but detailed interactions need to be identified. Weight management is the primary therapy; specific advice to reduce the glycaemic load
of the diet and reduce the intake of pro-inflammatory SFA and advanced glycation endproducts have provided promising results. It is
important that women with PCOS are educated about their increased risk of metabolic complications in order to make timely and appropriate
lifestyle modifications. Furthermore, well-designed robust studies are needed to evaluate the mechanisms behind the improvements observed
with dietary interventions.
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Introduction
Polycystic ovary syndrome (PCOS) is a common endocrine–
metabolic disorder affecting 12–18% of women, depending on
the diagnostic criteria used(1). Women with PCOS are at lifelong
risk of metabolic dysfunction and have increased risk of insulin
resistance (IR), type 2 diabetes mellitus (T2DM), dyslipidaemia
and atherosclerosis(2). The pathophysiology of PCOS is com-
plex and to some extent remains unclear; PCOS has a genetic
heritability and several potential genes have been identified.
However, research in this area is still in its infancy(3,4) and is
influenced by environmental factors, most notably diet and
increased body weight(5). The progression of research and
translation into clinical practice are hindered by the variability
of diagnostic and methodological issues endemic in studies of
PCOS(6).
Therefore the aim of this review is to present current
knowledge on the association between obesity, IR and PCOS
and in doing so highlight some of the diagnostic and metho-
dological challenges encountered in research and clinical
practice. Targeted searches were conducted to identify all
available data concerning the association of obesity and IR with
PCOS in order to summarise current knowledge on this topic up
to September 2016. PubMed and Science Direct were utilised in
order to locate relevant scientific reports and papers and ensure
an extensive review of the literature. Articles were considered if
they were peer reviewed, in English and included women with
PCOS (all diagnostic methods).
PCOS is a heterogeneous condition, the symptoms of which
often first present during the teenage years(7), though the
symptoms vary in their severity and can also change with age.
The symptoms include: menstrual irregularity, acne, excess
male pattern hair (hirsutism), male pattern alopecia, central
adiposity and fertility issues. Many of the symptoms associated
with PCOS have been shown to lead to a reduction in health-
related quality of life(8) and consequently depression and anxiety
are commonly reported in women with PCOS, independent of
body-weight status(9). Although obesity is a common feature of
PCOS, lean women with PCOS are also at increased disease risk
when compared with matched controls and can also suffer
debilitating symptoms(3). IR is not within any of the diagnostic
criteria; however, the majority of lean and overweight women
with PCOS have a form of IR intrinsic to PCOS and the com-
pensatory hyperinsulinaemia drives many of the phenotypic
features of PCOS(10). Hyperinsulinaemia promotes ovarian
hyperandrogenism which is present in 60–80% of women with
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PCOS; the androgen excess predominately results from increased
synthesis and release of ovarian androgens(10). In combination,
hyperinsulinaemia and hyperandrogenaemia can disrupt follicle
growth; this is accompanied by menstrual irregularity, anovula-
tory sub-fertility and accumulation of immature follicles(5).
The most widely used criteria for clinical diagnosis of PCOS
involve the presence of two of the three features listed in
Table 1, with the exclusion of other endocrine disorders as
developed by the European Society of Human Reproduction
and Embryology (ESHRE) and the American Society for
Reproductive Medicine (ASRM)(11), and are otherwise known as
the Rotterdam criteria.
There are distinct phenotypic presentations associated with
PCOS, and over the years several sub-categories have been
suggested. In 2012 at the National Institutes of Health workshop
there was a general consensus(12) and these categories are as
follows:
Androgen excess + ovulatory dysfunction;
Androgen excess + polycystic ovarian morphology;
Ovulatory dysfunction + polycystic ovarian morphology;
Androgen excess + ovulatory dysfunction + polycystic
ovarian morphology.
Several studies have highlighted that women with PCOS
who have regular ovulatory cycles often have normal insulin
sensitivity with milder metabolic abnormalities compared with
women with PCOS with ovulatory dysfunction(13,14). Women
who are anovulatory with hyperandrogenism are considered to
be at the greatest metabolic risk(15). Women with hyperandro-
genic PCOS generally present with a worse cardiometabolic
profile compared with women with non-hyperandrogenic
PCOS(16–18). It is generally agreed that the heterogeneity in
the PCOS population, studies not reporting specific PCOS
phenotypes, and the different methodologies used to report
IR and obesity/visceral fat have led to controversy in the rela-
tionship between obesity, IR and PCOS(6,19).
Obesity and polycystic ovary syndrome
Obesity is a common feature of PCOS. A meta-analysis of cross-
sectional and retrospective studies illustrated there is a greater
prevalence of obesity in PCOS; BMI > 30 kg/m2 (relative risk
2·77; 95% CI 1·88, 4·10; PCOS n 4165; controls n 4885) com-
pared with healthy women(20). The variability of data reporting
the prevalence of obesity in women with PCOS is likely to
reflect geographical, environmental and population variability
between studies. There is also uncertainty as to whether PCOS
causes weight gain and obesity or if obesity is linked to the
development of PCOS(21,22). Furthermore, clarification of
the role of adiposity in PCOS entails measurements other than
the measurement of BMI.
A meta-analysis clearly indicated that overweight or obese
women with PCOS had significantly worse metabolic and
reproductive outcomes when compared with healthy-weight
women with PCOS(23). Palomba et al.(24) confirmed that obesity
has a bidirectional relationship with PCOS and noted that
excessive weight gain could unmask a latent PCOS condition.
IR promotes the development of visceral adiposity in women
with PCOS, whereas the role of androgens is less clear(25). Tosi
et al.(26) have recently shown adiposity to be correlated with IR
and free testosterone levels (fat mass determined by dual-
energy X-ray absorptiometry (DXA), IR with euglycaemic clamp
and serum free testosterone by liquid chromatography–MS;
n 100 women with PCOS). However, insulin sensitivity, but not
adiposity, was found to be an independent predictor of free
testosterone concentrations. The central:peripheral fat ratio
identified by DXA was shown to be related to androgen levels
in twenty-four women with PCOS(27). Details of the complex
relationship between androgens and obesity are gradually
unfolding(28); adipocytes seem to be prone to hypertrophy
when exposed to androgen excess, and both adipose tissue
hypertrophy and hyperandrogenism are related to IR(29). What
is known is that weight reduction, even as little as 5%, improves
PCOS symptoms in overweight or obese women with
PCOS(30,31).
Whether women with PCOS present with increased abdom-
inal adiposity compared with women in the general population
continues to be debated. A diagnostic method of abdominal
obesity has not yet been defined and thus a range of methods is
used. Visceral adiposity index (VAI) is a simple surrogate marker
of visceral adiposity which utilises BMI, waist circumference, TAG
and HDL measurements and has been increasingly used since it
was established in 2010(32). Anthropometric studies that include
waist circumference measurements have shown that, regardless
of BMI, women with PCOS typically have an increased abdominal
fat distribution(33–36). A meta-analysis by Lim et al.(20) also
reported that women with PCOS had increased prevalence of
central obesity (risk ratio 1·73; 95% CI 1·31, 2·30; PCOS n 1191;
controls n 2396) (Fig. 1).
When body composition has been assessed by MRI, amounts
of visceral adipose tissue have been found to be similar in
women with PCOS and controls with comparable BMI (n 31),
despite increased waist:hip ratios(37) in the women with PCOS.
However, it is worth noting that in this study a number of
participants were only 1 week after ceasing the insulin-
sensitising agent, metformin, which has been shown to
reduce visceral adiposity in women with PCOS(38,39). Until
relatively recently, studies infrequently reported PCOS pheno-
types, which are known to have an impact on metabolic risk.
Panidis et al.(40), in a relatively small study (n 100 PCOS),
reported significantly higher VAI in the hyperandrogenism and
oligo/anovulation phenotype, when compared with other
phenotypes. Additionally, Androulakis et al.(41) reported that
women with PCOS with menstrual disorders had significantly
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Table 1. Diagnostic criteria for polycystic ovary syndrome (PCOS)(18)
Criteria
NIH
1990
Rotterdam
2003*
AE-
PCOS
Oligo-ovulation leading to oligomenorrhoea,
or anovulation leading to amenorrhoea
+ + /− + /−
Hyperandrogenism: clinical (hirsutism, male
pattern alopecia, acne) and/or biochemical
+ + /− +
Polycystic ovarian morphology on ultrasound + /− + /− + /−
NIH, National Institutes of Health; AE, androgen excess.
* The presence of two of the following three features with the exclusion of other
endocrine disorders.
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higher VAI when compared with PCOS without menstrual dis-
orders. A more recent, albeit relatively small, study(15) reported
a higher VAI in PCOS women with hyperandrogenism and
oligo/annovulation compared with other phenotypes. Further
research is clearly warranted with more accurate assessments of
adiposity for different PCOS phenotypes to help clarify the link
between obesity and PCOS.
Visceral adipose tissue is an important endocrine organ,
producing and releasing several adipokines; any specific dif-
ferences in resistin, leptin and visfatin in PCOS women com-
pared with controls remain uncertain; however, a clear role for
adiponectin in PCOS has been reported. Adiponectin is down-
regulated in obesity and is associated with IR; it also has strong
insulin-sensitising, anti-inflammatory and anti-diabetic func-
tions. Adiponectin circulates in different polymer complexes; it
has been suggested that its actions are mediated primarily by
the high-molecular-weight form of adiponectin(42). In 2014(43),
a meta-analysis based on thirty-eight trials (n 1944 PCOS;
n 1654 healthy controls) highlighted significantly lower total
adiponectin levels in PCOS women compared with healthy
controls, independent of BMI (weighted mean difference −2·67;
95% CI −3·22, −2·13). Visceral fat secretes less adiponectin
compared with subcutaneous fat(44), so the proposed increased
visceral adiposity in women with PCOS could be a reason
behind decreased high-molecular-weight adiponectin levels.
Metformin, a common treatment option for PCOS, was
associated with significantly elevated serum adiponectin
concentrations in women with PCOS (standard mean differ-
ences −0·43, 95% CI −0·75, −0·11)(45). In addition, it is likely that
adiponectin levels are different in the PCOS phenotypes as
suggested by Cankaya et al.(46); in a small study (n 40),
adolescents with androgen excess PCOS phenotype had
significantly lower high-molecular-weight adiponectin levels
compared with non-hyperandrogenic women. Testosterone has
been found to contribute to high-molecular-weight adiponectin
variance(47); however, in a 2009 meta-analysis testosterone
levels were not associated with adiponectin levels(48). Further
high-quality studies are needed to help clarify the role of
testosterone and adiponectin in PCOS.
Obesity is evidently complex and the location of excess
adiposity is key and all too rarely measured in combination with
presenting PCOS phenotypes. In particular, visceral fat plays a
key role in generating the insulin-resistant state which leads to
impaired glucose tolerance (IGT) and is a significant and
independent risk factor for T2DM(49).
Insulin resistance in polycystic ovary syndrome
A link between PCOS and IR was first highlighted in 1980,
whereby obese women with PCOS were shown to have an
increased insulin response to an oral glucose tolerance test
compared with obese controls(50). Prevalence rates of IR have
been reported between 44 and 85%(10,51). This variability is in
part due to differences in PCOS phenotype and ethnicity(15,17).
Reports of the prevalence of IR are limited by the methods used
to determine insulin sensitivity; the euglycaemic insulin clamp
technique is the most accurate method to diagnose IR, but its
high cost limits use; thus the surrogate markers, fasting insulin
and homeostasis model assessment of insulin resistance
(HOMA-IR)(52), are often reported.
IR and compensatory hyperinsulinaemia are fundamental to the
exacerbation of PCOS symptoms and metabolic complications(53).
Several studies have shown that the majority of women with
PCOS, both lean and overweight, have a form of IR that is
intrinsic to the syndrome(10). Researchers have shown that
obesity and PCOS have a separate and synergistic relationship
with IR(54). Defects in both insulin sensitivity and secretion are
present in lean women with PCOS(55). The pathogenesis of IR in
PCOS is complex and incompletely understood, though it
is agreed there is a post-binding defect in insulin receptor
signalling(51). There is an increasing body of evidence to
suggest a genetic susceptibility to PCOS and its associated IR as
well as evidence to suggest tha PCOS may also have fetal
origins due to androgen exposure at critical periods of growth
or due to intra-uterine growth restrictions(4).
IR is a common feature in annovulatory women with PCOS;
however, it is not as frequently observed in ovulatory women
with PCOS, even when hyperandrogenism is present(56).
Bil et al.(15) reported significantly greater HOMA-IR in the
androgen excess PCOS phenotype compared with non-
hyperandrogenic women (n 100). Some older studies have
failed to demonstrate IR in lean women with PCOS(57,58),
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Study of subgroup
Amato 2008(113)
Chae 2008(115)
Cheung 2008(116)
Glueck 2003(117)
Hahn 2007(118)
Total (95 % CI)
Total events
Test for overall effect: Z = 3.82 (P = 0.0001)
Heterogeneity: tau2= 0.10; 2= 30.73, df = 5 (P < 0.0001); I 2= 84 %
Bernasconi 1996(114)
Events
PCOS
Total Total Weight
Risk ratio Risk ratio
M-H, random, 95 % CI M-H, random, 95 % CIEvents
Control
113 170 21 34 17.8 % 1.08 (0.81, 1.43)
1.17 (0.81, 1.63)
1.59 (1.04, 2.43)
3.71 (2.26, 6.11)
1.97 (1.80, 2.14)
2.11 (1.56, 2.84)
1.73 (1.31, 2.30)
15.9 %
14.6 %
13.0 %
21.3 %
17.5 %
40
255
98
1887
82
Lower risk for PCOS    Higher risk for PCOS
0.01 0.1 1 10 100
21
37
14
821
29
52
143
277
138
411
1191 2396 100.0 %
749 943
32
33
147
118
306
Fig. 1. Meta-analysis(113–118) of the prevalence of central obesity in women with and without polycystic ovary syndrome (PCOS) (taken from Lim et al.(20)).
M-H, Mantel–Haenszel.
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although this may be accounted for by the inability to distin-
guish between the different PCOS phenotypes which resulted in
the inclusion of women who were ovulatory.
Chronic inflammation and its role in IR in PCOS continues to
be investigated(59). The increase in multiple markers of
inflammation such as leucocyte count, C-reactive protein, IL-18,
protein-1, and monocyte chemo-attractant in addition to
increased oxidative stress and endothelial dysfunction are evi-
dence that PCOS is commonly coupled with low-level systemic
inflammation(60). However, there are limited studies that assess
the presence of chronic inflammation independent of adiposity
in women with PCOS. Circulating markers of oxidative stress
are abnormal in women with PCOS independent of weight
excess and IR(61). The close association between oxidative
stress and inflammation make it difficult to determine their
individual contribution to PCOS and the mechanism of oxida-
tive stress-induced IR remains unclear(62). Oxidative stress and
inflammation markers are positively correlated with androgen
levels in PCOS patients(63); thus they seem to contribute to
hyperandrogenaemia, but detailed interactions still need to be
identified, and as of yet few investigations have been done.
Insulin acts directly on the ovary by stimulating the thecal
cells to increase androgen production and by activation of the
cytochrome P450c17α(57,64). Hyperinsulinaemia further exacer-
bates the pathogenesis of PCOS by inhibiting the production of
insulin-like growth factor-1 (IGF-1) binding protein in the liver,
leading to elevated circulating levels of IGF-1, which in
turn stimulates ovarian thecal cell androgen production(65).
Hyperinsulinaemia reduces hepatic production of sex
hormone-binding globulin, thus increasing free testosterone
levels(66). In combination, hyperinsulinaemia and hyperandro-
genaemia can disrupt follicle growth; this is accompanied by
menstrual irregularity, anovulatory sub-fertility and accumula-
tion of immature follicles(51). Diamanti-Kandarakis & Dunaif(51)
in a review described the modulating action of insulin on
ovarian steroidogenesis as well as the importance of the insulin
signalling pathway in the control of ovulation.
Women with PCOS commonly have postprandial
dysglycaemia(67,68), which reflects peripheral, primarily skeletal
muscle, IR. In lean women with PCOS hyperinsulinaemia is
often evident postprandially but not in the fasted state(69).
IR and compensatory hyperinsulinaemia have also been
proposed as a cause of reactive hypoglycaemia in women with
PCOS. A cross-sectional study of sixty-four lean young women
with PCOS reported the rate of reactive hypoglycaema to be
50%(70). A survey of clinical practice (n 88) also indicated a high
prevalence of hypoglycaemia; self-reported in 71% of women
with PCOS(36). A recent study also indicated a higher prevalence
of reactive hypoglycaemia in PCOS (n 88) compared with
age- and BMI-matched controls (n 34), though a much lower
prevalence of 17%(71). Robust studies investigating hypo-
glycaemia are sparse.
Impaired glucose tolerance and type 2 diabetes mellitus
The prevalence of IGT and T2DM in women with PCOS is
substantially higher compared with age- and weight-matched
healthy women; a meta-analysis of cross-sectional and cohort
studies reported an OR of 2·54 (95% CI 1·44, 4·47) for OGT and
4·00 (95% CI 1·97, 8·10) for T2DM(72). Differences in the diag-
nostic criteria for IGT and PCOS were evident, and there were
inadequate data to allow for PCOS phenotype sub-analysis;
additionally, differences in ethnicity and BMI have resulted in
variable risk estimates between PCOS studies. Studies in the
USA have indicated a prevalence of 23–35% for IGT and 4–10%
for T2DM(67,68), whereas in non-US studies prevalence rates in
women with PCOS are elevated although not all to the same
extent, with prevalence rates of 16% for IGT and 2·5% for
T2DM described in an Italian cohort(73). In the US studies, even
lean women with PCOS had increased rates of IGT and T2DM
compared with healthy controls(67), the onset of IGT occurring
in their thirties and forties which is earlier than the normal
population(74). A more recent longitudinal study following
women for at least 10 years reported that the age-standardised
prevalence of diabetes at the end of follow-up was 39·3%,
significantly higher than in healthy women (prevalence of
5·8%)(75).
The Royal College of Obstetrics and Gynaecology 2014
guidelines(76) state that women presenting with PCOS with a
BMI ≥ 25 kg/m2 and lean women with PCOS, but who have
additional risk factors such as advanced age (> 40 years),
personal history of gestational diabetes or family history of
T2DM, should have a 2-h post-75 g oral glucose tolerance test.
Metabolic syndrome and non-alcoholic liver disease in
polycystic ovary syndrome
PCOS commonly includes many metabolic syndrome compo-
nents, such as abdominal obesity, dyslipidaemia, hyperglycae-
mia and hypertension, which predispose women with PCOS to
the development of T2DM and CVD. There is a higher pre-
valence of the metabolic syndrome in women with PCOS
compared with women in the general population(77), estimated
to be between 34 and 46%, based on studies of Caucasian
women with PCOS from the USA using the National Cholesterol
Education Program Adult Treatment Panel III criteria(78–80).
Women diagnosed with PCOS using National Institutes of
Health criteria are more likely to have a higher prevalence of
the metabolic syndrome compared with controls, compared
with women diagnosed with PCOS using the ESHRE/ASRM
guidelines(72,81). Studies that clearly indicate the prevalence of
the metabolic syndrome in differing PCOS phenotypes are
lacking.
IR and obesity are strong predictors of non-alcoholic fatty
liver disease (NAFLD)(82,83); thus it is not surprising that there is
a higher prevalence of NAFLD in women with PCOS compared
with age- and BMI-matched controls; prevalence rates ranging
from 27 to 62%(84–87). This variation can be attributed to dif-
ferences in laboratory diagnostic criteria (for example, liver
function tests, liver imaging studies, liver biopsy) and differ-
ences in study populations relating to ethnicity, age, BMI and
PCOS diagnostic criteria(88). Vassilatou(88) has highlighted the
increasing evidence that hyperandrogenism is related to NAFLD
in PCOS and suggested that hyperandrogensim should be
considered as an additional link in the synergy with obesity
and IR for the development of NAFLD in PCOS. However,
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sub-analyses with the PCOS phenotypes were not reported and
would seem prudent for further evaluation.
Of clinical importance, the prevalence of non-alcoholic
steatohepatitis (NASH) in women with PCOS is particularly
high(89). Bariatric surgery has shown beneficial outcomes on
NASH(90). With the exception of weight loss through lifestyle
modification and encouraging exercise in obese women, few
evidence-based effective treatments specifically target NAFLD/
NASH in women with PCOS(91).
Dietary influences of the metabolic aspects of polycystic
ovary syndrome
With no cure for PCOS, clinical management focuses on treating
the presenting symptoms. Lifestyle management is advocated as
the primary therapy in overweight and obese women with
PCOS since even a modest weight loss of just 5–10%, without
medical intervention, improves many of the symptoms asso-
ciated with PCOS(30,92,93).
The optimal method of achieving sustainable weight loss is
under constant debate; studies demonstrating the clinical ben-
efits of weight loss in women with PCOS incorporate a variety
of methods to reduce energy intake and achieve a negative
energy balance(94). Behaviour-change strategies have long been
recognised as being instrumental in managing chronic condi-
tions, particularly weight management. However, lifestyle
modification programmes are often reported to have low
compliance and high dropout rates(95). Furthermore, many
overweight or obese women with PCOS are not following a diet
that would promote weight loss(96). Bariatric surgery, on the
other hand, in women with PCOS has resulted in substantial
weight loss and marked improvement of multiple biochemical
abnormalities(97,98). A recent meta-analysis of thirteen studies
(2130 women) reported a reduction in the incidence of PCOS
preoperatively from 45·6%, to 6·8% at 12-month follow-up(99).
Dietary modification to improve IR may produce benefits
greater than those achieved by modest weight loss and would
also be suitable for lean IR women with PCOS. Modifying the
carbohydrate content and fatty acid content of the diet have
both been proposed as methods to improve insulin sensitivity.
The concept of a low-glycaemic index (GI) diet aims to reduce
the glycaemic load (GL) and hence insulin response to ingested
foods and drinks. Greater improvement in insulin sensitivity
and regular menses were reported after weight loss with a low
dietary GI approach (n 29) compared with weight loss through
conventional healthy eating (n 20)(100). In this study, women
were followed for 12 months or until they achieved 7% weight
loss. Barr et al.(101) also demonstrated an improvement in
insulin sensitivity after following an isoenergetic diet with a
reduction in dietary GI in twenty-one women with PCOS over a
12-week intervention period. Furthermore, one study(102)
reported a reduction in IR after a 12-week hypoenergetic diet,
high in protein (30% protein: n 23), with a low GL compared
with a conventional hypoenergetic healthy eating intervention
(15% protein: n 26). A low-GL diet in lean women with PCOS
(n 41) resulted in a reduction in waist circumference(36). These
small studies suggest a benefit for promoting lower GI dietary
advice to lean women with PCOS, many of whom are also
insulin resistant. However, exploring the mechanisms behind
the intervention and assessing IR with the euglycaemic clamp
technique and evaluating the effect of modifying dietary GI in a
subgroup of IR women with PCOS is prudent to improving the
evidence base for dietary recommendations.
Inflammation is implicated in the pathogenesis of PCOS;
dietary constituents such as SFA can influence inflammatory
mediators, such as TNF-α and IL-1β and disrupt insulin
signalling(103,104). Conversely, MUFA and PUFA do not interrupt
metabolism and inflammation to the same extent. SFA intake
has been shown to influence glucose metabolism through the
altering of insulin signalling and cell membrane function, with a
diet high in SFA associated with a decrease in insulin sensitivity
when compared with a high-MUFA diet(103). Of interest, it has
been reported that 68% of women with PCOS had a total fat
intake greater than a 35% contribution to total energy, with
SFA intake accounting for 12% of total energy, substantially
exceeding the reference nutrient intake (<10% energy)(105,106).
Thus, a reduction of total fat intake should focus on lowering
SFA intake concurrently with the encouragement of the main-
tenance of MUFA and PUFA in women with PCOS. There is
some evidence to show that by reducing the consumption of
saturated fat(107) and reducing the GI and GL of the diet(107),
insulin sensitivity can be improved in insulin-resistant popula-
tions; however, there remains a paucity of studies in women
with PCOS(108).
Advanced glycation end products (AGEs) are elevated in
PCOS(109); these pro-inflammatory molecules trigger a state of
intracellular oxidative stress and inflammation after binding to
their cell membrane receptors (RAGE). They are highly reactive
molecules formed by non-enzymic reactions of carbonyl group
of carbohydrates with free amino groups of proteins, nucleic
acids or lipids. AGEs within the body are from endogenous
production or ingested in high amounts from cooked fast
food(110). A small study(111) (twenty-three PCOS participants)
has shown that a 2-month intervention of a low dietary intake of
AGEs is associated with improved levels of serum testosterone,
oxidative stress and HOMA-IR in PCOS. The role of dietary
AGEs as mediators of metabolic and reproductive alterations in
PCOS is an exciting and emerging area of dietary modification
for PCOS.
An area yet to be explored in PCOS is the role of the gut
microbiota(112), which could influence glucose homeostasis and
insulin sensitivity by fermenting indigestible dietary compo-
nents to produce SCFA. These SCFA have been shown to
beneficially modulate adipose tissue, skeletal muscle and liver
tissue function. Furthermore, research, including well-designed
robust studies, is needed to evaluate the mechanisms behind
the improvements observed with dietary modification and
inherent with all weight-reduction interventions to improve
adherence to interventions and weight maintenance.
Conclusion
PCOS is a diverse condition that manifests itself in a variety of
symptoms linked to ovulatory dysfunction and the over-
production of androgens. Women with PCOS are at a greater
risk of metabolic dysfunction and consequently need regular
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monitoring for risk of diabetes and CVD. Whilst treatment is
mostly aimed at addressing the presenting symptoms, dietary
adaptations to improve metabolic symptoms will be beneficial
for long-term health. Young women with PCOS often present to
healthcare professionals due to infrequent menses or infertility;
it is at this stage that they can be educated about the increased
long-term risk of metabolic complications of the syndrome in
order to make timely and appropriate lifestyle modifications.
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